ArticleVeterinary research communications2026
Safe and effective control of Mycoplasma gallisepticum: pharmacokinetic and residue profiling of doxycycline combined with quercetin nanomicelles.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although doxycycline is widely used to combat Mycoplasma gallisepticum (MG), misuse promotes antimicrobial resistance. Quercetin exhibits antibacterial potential; however, its application is limited by poor bioavailability, and its nanomicelle-based delivery with doxycycline remains uninvestigated. This study evaluated the efficacy, pharmacokinetics, and residue depletion of doxycycline combined with quercetin and quercetin nanomicelles against MG infection in broilers using a validated green high-performance liquid chromatography approach. One-day-old chicks were divided into seven groups: negative and positive controls, and treatment groups that received doxycycline, quercetin, or quercetin nanomicelles orally at doses of 25, 50, and 50 mg/kg body weight, respectively, either alone or in combination, for five days post-challenge. Pharmacokinetic parameters and residue depletion were investigated in treated groups at multiple time points. Tracheal and lung samples were collected at two intervals for MG enumeration and virulence gene expression. Quercetin and its nanomicelles displayed minimum inhibitory concentrations (MICs) of 0.47 and 0.02 µg/mL, respectively; their combinations with doxycycline had fractional inhibitory concentration indices of 6 and 0.375, respectively. Nanomicelles were characterized by size, polydispersity index, zeta potential, and encapsulation efficiency values of 345.66 nm, 0.14, 19.1 mV, and 96.1%, respectively, with no cytotoxicity up to 8× MIC. In vivo, the greatest reductions in MG counts and in mgc2, adrA, and crmA expression were observed in nanomicelle-treated groups. Co-administration of doxycycline with nanomicellar quercetin improved systemic exposure, prolonged serum persistence above the MIC, and supported extended dosing intervals while maintaining favorable tissue depletion profiles. Conversely, conventional quercetin negatively influenced doxycycline pharmacokinetics, causing therapeutic failure.
Indexed as
Identifiers
42406229What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.